Compare SOTK & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOTK | INKT |
|---|---|---|
| Founded | 1975 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.8M | 57.6M |
| IPO Year | 1995 | 2021 |
| Metric | SOTK | INKT |
|---|---|---|
| Price | $4.08 | $9.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 28.9K | ★ 147.7K |
| Earning Date | 01-13-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $20,504,381.00 | N/A |
| Revenue This Year | $4.02 | N/A |
| Revenue Next Year | $10.95 | N/A |
| P/E Ratio | $51.69 | ★ N/A |
| Revenue Growth | ★ 4.08 | N/A |
| 52 Week Low | $3.23 | $6.66 |
| 52 Week High | $5.15 | $76.00 |
| Indicator | SOTK | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 49.37 | 39.91 |
| Support Level | $4.03 | $6.80 |
| Resistance Level | $4.18 | $12.64 |
| Average True Range (ATR) | 0.20 | 0.71 |
| MACD | 0.00 | -0.16 |
| Stochastic Oscillator | 49.29 | 7.28 |
Sono-Tek Corp design and manufacture of ultrasonic coating systems for applying precise, thin film coatings to add functional properties, protect or strengthen surfaces on parts and components for the microelectronics/electronics, alternative energy, medical, industrial and emerging research & development/other markets. The company design and manufacture custom-engineered ultrasonic coating systems incorporating its patented technology, in combination with strong applications engineering knowledge, to assist its customers in achieving their desired coating solutions.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.